Healios KK Announces Key Management Changes

TipRanksDec 19 11:57

Stocks that moved the previous day part 2 PKSHA, Fujikura, Asahi Kasei ETC.

Stock Name <Code> 10-day Closing Price ⇒ Change from Previous Day Beauty Garage <3180> 1297 -110 The first half has seen a significant decrease in operating profit due to lower than planned results. Senshu Electric <9824> 5380 -240 It had experienced a sharp rise after the Earnings Reports. Fujikura <5803> 5851 -337 Profit-taking Sell and other supply-demand factors might have led to this. PKSHA Technology <3993> 3965 -280Tokai Tokyo Securities has downgraded its investment recommendation. Cosmos Pharmaceutical <3349>

Fisco JapanDec 11 06:32

Active and newly listed stocks during the morning session.

*Learning situation <2301> 2006 +231 results exceeded expectations in the previous period, with a forecast of double-digit operating profit growth for this period. *Topcon <7732> 1928 +171.5 reported to have entered the bidding process for privatization. *Nippon Paint Holdings <4612> 1093 +63 SMBC Nikko Securities has raised its target stock price. *Nippon Sheet Glass <5202> 349 +20 it is reported that they aim to release automotive glass materials from leftover materials by 2026. *Saizeriya <7581> 5820 +280 middle.

Fisco JapanDec 10 13:06

Helios Research Memo (6): Revenue for the interim period ending December 2024 will significantly increase due to the recognition of contract advance payments.

■ The performance trends of Helios <4593> 1. Performance for the interim period ending December 2024 The consolidated performance for the interim period ending December 2024 is 508 million yen in sales revenue (compared to 401 million yen in the same period last year, an increase of 372.4%), an operating loss of 1,331 million yen (compared to a loss of 1,555 million yen in the same period last year), a pre-tax loss of 2,968 million yen (compared to a loss of 1,321 million yen in the same period last year), and an interim loss attributable to the owners of the parent company of 2,958 million yen (compared to a loss of 1,392 million yen in the same period last year). The increase in sales revenue is due to a

Fisco JapanDec 10 12:06

Helios Research Memo (5): Business partnership with Alfresa and concluded a non-exclusive license agreement with an Astellas subsidiary.

■ The status of business partnerships and licensing agreements for Helios <4593> 1. Business partnership agreement with Alfresa In June 2024, a basic business partnership agreement concerning the distribution and sale of products handled by Alfresa, the leading domestic drug distribution company, was concluded, along with a purchase agreement for ordinary corporate bonds totaling 1.6 billion yen (1st and 2nd issues). The specific content of the business partnership is as follows: 1) Exclusive wholesale distribution rights for the company's pipeline products, including HLCM051, in the domestic market.

Fisco JapanDec 10 12:05

Helios Research Memo (4): Analyzing clinical trial data for stroke in Japan and the United States, considering trial designs with a high probability of obtaining approval.

■ Helios <4593> Development Pipeline 3. HLCM051 (Stroke Treatment Drug) Stroke refers to a condition where the brain's blood vessels become blocked, resulting in the deprivation of nutrients to the cells beyond that point, which disrupts brain function. Symptoms vary depending on the location of the blocked blood vessel, but once the disease occurs, even if the person survives, in many cases, sequelae such as paralysis or language disorders remain. According to the company's financial presentation materials, the annual number of new cases is 0.33 million in Japan, 0.69 million in the USA, 0.84 million in the European Index, China.

Fisco JapanDec 10 12:04